Design and implementation of the OFELIA FP7 facility: The European OpenFlow testbed

The growth of the Internet in terms of number of devices, the number of networks associated to each device and the mobility of devices and users makes the operation and management of the Internet network infrastructure a very complex challenge. In order to address this challenge, innovative solutions and ideas must be tested and evaluated in real network environments and not only based on simulations or laboratory setups. OFELIA is an European FP7 project and its main objective is to address the aforementioned challenge by building and operating a multi-layer, multi-technology and geographically distributed Future Internet testbed facility, where the network itself is precisely controlled and programmed by the experimenter using the emerging OpenFlow technology. This paper reports on the work done during the first half of the project, the lessons learned as well as the key advantages of the OFELIA facility for developing and testing new networking ideas. An overview on the challenges that have been faced on the design and implementation of the testbed facility is described, including the OFELIA Control Framework testbed management software. In addition, early operational experience of the facility since it was opened to the general public, providing five different testbeds or islands, is described

NFV Orchestration over Disaggregated Metro Optical Networks with End-to-End Multi-Layer Slicing enabling Crowdsourced Live Video Streaming

Network infrastructure must support emerging applications, fulfill 5G requirements, and respond to the sudden increase of societal need for remote communications. Remarkably, crowdsourced live video streaming (CLVS) challenges operators' infrastructure with tides of users attending major sport or public events that demand high bandwidth and low latency jointly with computing capabilities at the networks' edge. The Metro-Haul project entered the scene proposing a cost-effective, agile, and disaggregated infrastructure for the metro segment encompassing optical and packet resources jointly with computing capabilities. Recently, a major Metro-Haul outcome took the form of a field trial of network function virtualization (NFV) orchestration over the multi-layer packet and disaggregated optical network testbed that demonstrated a CLVS use case. We showcased the average service creation time below 5 min, which met the key performance indicator as defined by the 5G infrastructure public private partnership. In this paper, we expand our field trial demonstration with a detailed view of the Metro-Haul testbed for the CLVS use case, the employed components, and their performance. The throughput of the service is increased from approximately 9.6 Gbps up to 35 Gbps per virtual local area network with high-performance VNFs based on single-root input/output virtualization technology

Cognitive Dynamic Optical Networks

Cognitive networks are a promising solution for the control of heterogeneous optical networks. We review their fundamentals as well as a number of applications developed in the framework of the EU FP7 CHRON project

The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study

Background: Immediate breast reconstruction (IBR) is routinely offered to improve quality-of-life for women requiring mastectomy, but there are concerns that more complex surgery may delay adjuvant oncological treatments and compromise long-term outcomes. High-quality evidence is lacking. The iBRA-2 study aimed to investigate the impact of IBR on time to adjuvant therapy. Methods: Consecutive women undergoing mastectomy ± IBR for breast cancer July–December, 2016 were included. Patient demographics, operative, oncological and complication data were collected. Time from last definitive cancer surgery to first adjuvant treatment for patients undergoing mastectomy ± IBR were compared and risk factors associated with delays explored. Results: A total of 2540 patients were recruited from 76 centres; 1008 (39.7%) underwent IBR (implant-only [n = 675, 26.6%]; pedicled flaps [n = 105,4.1%] and free-flaps [n = 228, 8.9%]). Complications requiring re-admission or re-operation were significantly more common in patients undergoing IBR than those receiving mastectomy. Adjuvant chemotherapy or radiotherapy was required by 1235 (48.6%) patients. No clinically significant differences were seen in time to adjuvant therapy between patient groups but major complications irrespective of surgery received were significantly associated with treatment delays. Conclusions: IBR does not result in clinically significant delays to adjuvant therapy, but post-operative complications are associated with treatment delays. Strategies to minimise complications, including careful patient selection, are required to improve outcomes for patients

Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Abstract: Background: The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods: This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Findings: Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions: The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown